$TARA
Protara Therapeutics, Inc. Stock $tara

$tara Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000117184319001687 Filed on March 13, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.590M	$2.720M	$9.520M
YoY Change	13.1%	14.29%	9.68%
% of Gross Profit
Research & Development	$4.048M	$2.660M	$11.85M
YoY Change	-0.56%	-17.13%	-45.37%
% of Gross Profit
Depreciation & Amortization	$174.0K	$40.00K	$115.0K
YoY Change	443.75%	33.33%	-22.3%
% of Gross Profit
Operating Expenses	$6.637M	$5.385M	$21.37M
YoY Change	4.27%	-3.67%	-29.61%
Operating Profit	-$6.637M		-$21.37M
YoY Change	4.27%		-29.61%
Interest Expense	$110.0K	$130.0K	$440.0K
YoY Change	22.22%	30.0%	69.23%
% of Operating Profit
Other Income/Expense, Net	$106.0K	$0.00	$643.0K
YoY Change	-62.68%	-100.0%	61.56%
Pretax Income	-$6.530M	-$5.260M	-$17.86M
YoY Change	7.4%	-5.23%	-28.01%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$6.531M	-$5.260M	-$20.73M
YoY Change	7.4%	-5.23%	-30.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$13.60M	-$10.96M	-$46.07M
COMMON SHARES
Basic Shares Outstanding	19.24M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.80M	$21.90M	$21.90M
YoY Change	-54.35%	-47.98%	-47.98%
Cash & Equivalents	$16.76M	$19.37M	$19.40M
Short-Term Investments	$0.00	$2.500M	$2.500M
Other Short-Term Assets	$1.100M	$1.400M	$1.400M
YoY Change	-8.33%	7.69%	7.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$17.93M	$23.24M	$23.20M
YoY Change	-52.85%	-46.56%	-46.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$105.0K	$263.0K	$300.0K
YoY Change	-55.51%	1.54%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Total Long-Term Assets	$127.0K	$285.0K	$300.0K
YoY Change	-73.32%	-42.89%	-40.0%
TOTAL ASSETS
Total Short-Term Assets	$17.93M	$23.24M	$23.20M
Total Long-Term Assets	$127.0K	$285.0K	$300.0K
Total Assets	$18.06M	$23.52M	$23.50M
YoY Change	-53.1%	-46.52%	-46.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.676M	$441.0K	$400.0K
YoY Change	-76.11%	51.55%	33.33%
Accrued Expenses	$1.559M	$2.637M	$2.600M
YoY Change	-22.21%	-70.53%	-70.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.370M	$3.078M	$3.100M
YoY Change	-62.64%	-66.69%	-66.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.370M	$3.078M	$3.100M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.370M	$3.078M	$3.100M
YoY Change	-62.64%	-66.69%	-66.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$217.0M	-$210.5M
YoY Change	10.82%	10.92%
Common Stock	$19.00K	$0.00
YoY Change	5.56%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.69M	$20.44M	$20.40M
YoY Change
Total Liabilities & Shareholders Equity	$18.06M	$23.52M	$23.50M
YoY Change	-53.1%	-46.52%	-46.59%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$6.531M	-$5.260M	-$20.73M
YoY Change	7.4%	-5.23%	-30.82%
Depreciation, Depletion And Amortization	$174.0K	$40.00K	$115.0K
YoY Change	443.75%	33.33%	-22.3%
Cash From Operating Activities	-$5.092M	-$4.310M	-$23.23M
YoY Change	-6.67%	-24.39%	3.94%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	-$100.0K	$119.0K
YoY Change	77.78%	400.0%	240.0%
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$5.510M	$18.55M
YoY Change	-73.71%	-14.71%	-215.5%
Cash From Investing Activities	$2.484M	$5.420M	$18.43M
YoY Change	-73.87%	-15.97%	-214.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		50.00K	2.985M
YoY Change		-16.67%	-87.05%
NET CHANGE
Cash From Operating Activities	-5.092M	-4.310M	-23.23M
Cash From Investing Activities	2.484M	5.420M	18.43M
Cash From Financing Activities		50.00K	2.985M
Net Change In Cash	-2.608M	1.160M	-1.799M
YoY Change	-162.3%	43.21%	-88.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.092M	-$4.310M	-$23.23M
Capital Expenditures	$16.00K	-$100.0K	$119.0K
Free Cash Flow	-$5.108M	-$4.210M	-$23.35M
YoY Change	-6.53%	-25.88%	4.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17619418
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19243651
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018Q2	dei	Entity Public Float EntityPublicFloat	26200000
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2017	prto	Accretion Of Redeemable Convertible Preferred Stock To Redemption Value AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue	6747000
CY2018	prto	Accretion Of Redeemable Convertible Preferred Stock To Redemption Value AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
CY2016	prto	Accretion Of Redeemable Convertible Preferred Stock To Redemption Value AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19243651
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17674729
CY2018Q4	prto	Contracted Service Costs ContractedServiceCosts	968000
CY2017Q4	prto	Contracted Service Costs ContractedServiceCosts	7218000
CY2017	prto	Deferred Tax Assets Increase Decrease From Revaluation Due To Tax Rate Change DeferredTaxAssetsIncreaseDecreaseFromRevaluationDueToTaxRateChange	-2200000
CY2018	prto	Effective Income Tax Rate Reconciliation382 Limitation Amount EffectiveIncomeTaxRateReconciliation382LimitationAmount
CY2017	prto	Effective Income Tax Rate Reconciliation382 Limitation Amount EffectiveIncomeTaxRateReconciliation382LimitationAmount	64975000
CY2016	prto	Effective Income Tax Rate Reconciliation382 Limitation Amount EffectiveIncomeTaxRateReconciliation382LimitationAmount
CY2018	prto	Foreign Currency Remeasurement Gain Loss ForeignCurrencyRemeasurementGainLoss	25000
CY2017	prto	Foreign Currency Remeasurement Gain Loss ForeignCurrencyRemeasurementGainLoss	173000
CY2016	prto	Foreign Currency Remeasurement Gain Loss ForeignCurrencyRemeasurementGainLoss	-76000
CY2018	prto	Income Tax Reconciliation Orphan Drug Tax Credit Permanent Addback IncomeTaxReconciliationOrphanDrugTaxCreditPermanentAddback
CY2017	prto	Income Tax Reconciliation Orphan Drug Tax Credit Permanent Addback IncomeTaxReconciliationOrphanDrugTaxCreditPermanentAddback	1751000
CY2016	prto	Income Tax Reconciliation Orphan Drug Tax Credit Permanent Addback IncomeTaxReconciliationOrphanDrugTaxCreditPermanentAddback	1437000
CY2018	prto	Income Tax Reconciliation State Income Taxes Net Of Federal Benefit IncomeTaxReconciliationStateIncomeTaxesNetOfFederalBenefit	-958000
CY2017	prto	Income Tax Reconciliation State Income Taxes Net Of Federal Benefit IncomeTaxReconciliationStateIncomeTaxesNetOfFederalBenefit	-853000
CY2016	prto	Income Tax Reconciliation State Income Taxes Net Of Federal Benefit IncomeTaxReconciliationStateIncomeTaxesNetOfFederalBenefit	-498000
CY2018Q1	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-6081000
CY2018Q2	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-4879000
CY2018Q3	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-4510000
CY2018Q4	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-5259000
CY2017Q1	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-6498000
CY2017Q2	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-5608000
CY2017Q3	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-19054000
CY2017Q4	prto	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-5551000
CY2017Q3	prto	Operating Leases Increase In Office Space OperatingLeasesIncreaseInOfficeSpace	2552
CY2017Q3	prto	Operating Leases Notice Required To Extend Term OperatingLeasesNoticeRequiredToExtendTerm	P180D
CY2018Q4	prto	Operating Loss Carryforwards Net Indefinite Lived OperatingLossCarryforwardsNetIndefiniteLived	14700000
CY2018	prto	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	2853000
CY2017	prto	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	1288000
CY2016	prto	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
CY2018	prto	Proceeds From Issuance Of Common Stock Under Espp ProceedsFromIssuanceOfCommonStockUnderESPP	132000
CY2017	prto	Proceeds From Issuance Of Common Stock Under Espp ProceedsFromIssuanceOfCommonStockUnderESPP	130000
CY2016	prto	Proceeds From Issuance Of Common Stock Under Espp ProceedsFromIssuanceOfCommonStockUnderESPP	11000
CY2018	prto	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
CY2017	prto	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	21523000
CY2016	prto	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
CY2002Q1	prto	Royalty Payment Percentage Of Net Sales RoyaltyPaymentPercentageOfNetSales	0.025
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	441000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	291000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	51000
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-131000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2637000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8949000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	279000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	413000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	827000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	712000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	209366000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202953000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	197000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	108000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3343000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3227000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3429000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3429000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3227000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3343000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26710001
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24793847
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2166254
CY2017Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	7500
CY2018Q4	us-gaap	Assets Assets	23521000
CY2017Q4	us-gaap	Assets Assets	43979000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	23236000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	43480000
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20849000
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32633000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19243651
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17674729
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	19000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.13
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.72
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25877695
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2496000
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	20991000
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2496000
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	20971000
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	20000
CY2018Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	2496000
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	20971000
CY2018	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2017	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19371000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21170000
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	21900000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21192000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36414000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40045000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19393000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1799000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15222000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3639000
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27394852
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	59943000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	18000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20710000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29978000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28515000
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk and Off-Balance Sheet Risk</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and short-term investments. The Company's cash and cash equivalents are held in accounts with financial institutions that management believes are creditworthy. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> financial instruments with off-balance sheet risk of loss.</div></div></div></div></div></div></div>
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	132000
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	191000
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	360000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12358000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6949000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	61038000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6742000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2651000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37237000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	169000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	202000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	321000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	3122000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	2244000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	21223000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1782000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1262000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1353000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	411000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	399000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	544000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12358000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6949000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61038000
CY2018	us-gaap	Depreciation Depreciation	115000
CY2017	us-gaap	Depreciation Depreciation	148000
CY2016	us-gaap	Depreciation Depreciation	123000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	180000
CY2016	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-76000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1390000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1318000
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y146D
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y146D
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4600000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4200000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	127000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9524000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8676000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9836000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17855000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-24803000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15860000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2874000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5161000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12666000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20729000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-29964000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-28526000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	0
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5409000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-54319000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8804000
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2202000
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	602000
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1752000
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4304000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4348000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10186000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9696000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	4000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	430000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	325000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	689000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	430000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-520000
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	65000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1466000
CY2017	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	5495000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4846000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6162000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4161000
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	22000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210470000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189741000
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	193000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1073000
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-49000
CY2017	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	46000
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	26000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-141000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-297000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-246000
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	436000
CY2017	us-gaap	Investment Income Net InvestmentIncomeNet	259000
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000
CY2017Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2017Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y90D
CY2018Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	22000
CY2017Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	22000
CY2018Q4	us-gaap	Liabilities Liabilities	3078000
CY2017Q4	us-gaap	Liabilities Liabilities	9240000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23521000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43979000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3078000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9240000
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2017Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2018Q4	us-gaap	Loans Pledged As Collateral LoansPledgedAsCollateral	22000
CY2017Q4	us-gaap	Loans Pledged As Collateral LoansPledgedAsCollateral	22000
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 23px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 8px"> </td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Organization and Operations</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proteon Therapeutics, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on the development of novel, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease. The Company was formed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2001 </div>and incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 24, 2006.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> generated any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including regulatory approval of products, uncertainty of market acceptance of products, competition from therapeutic alternatives and larger companies, compliance with government regulations, protection of proprietary technology, dependence on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and product liability.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Liquidity and Going Concern </div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company had cash, cash equivalents and available-for-sale investments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21.9</div> million. The Company believes that its existing cash, cash equivalents and available-for-sale investments will be sufficient to fund operations and capital expenditures into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> The Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$210.5</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on these available cash resources, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have sufficient cash on hand to support current operations for at least the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months from the date of filing this Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K. This condition raises substantial doubt about the Company’s ability to continue as a going concern.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company’s plans to address this condition include pursuing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of the following options to secure additional funding, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of which can be guaranteed or are entirely within our control:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 4%; text-align: justify"> </td> <td style="white-space: nowrap; width: 4%; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt">•</div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt">raise additional funding through the possible sale of additional shares of the Company’s common stock, including public or private equity financings, and/or possible debt financings; and </div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 4%; text-align: justify"> </td> <td style="white-space: nowrap; width: 4%; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt">•</div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt">use the worldwide commercial rights to vonapanitase currently held by the Company to establish partnerships for the development and commercialization of vonapanitase in all or parts of Europe and other countries outside of the United States to secure additional funding.</div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance, however, that the Company will receive cash proceeds from any of these potential sources or to the extent cash proceeds are received those proceeds would be sufficient to support our current operating plan for at least the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months from the date of filing this Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements of Accounting Standards Codification (ASC) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,</div> <div style="display: inline; font-style: italic;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</div> management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the financial statements are issued. This evaluation initially does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> take into consideration the potential mitigating effect of management’s plans that have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) it is probable that the plans will be effectively implemented within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the financial statements are issued, and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the financial statements are issued.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,</div> the future receipt of potential funding from the Company’s partners and other resources cannot be considered probable at this time because <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of the Company’s current plans have been finalized at the time of filing this Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K and the implementation of any such plan is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> probable of being effectively implemented as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date these financial statements are issued.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <!-- Field: Page; Sequence: 92; Value: 3 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company believes that its approximate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21.9</div> million in cash, cash equivalents and marketable securities at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> as described above, would allow it to fund its planned operations into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> This estimate assumes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> equity financings, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> debt financings and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> funding from new partnership agreements. Accordingly, the timing and nature of activities contemplated for the remainder of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and thereafter will be conducted subject to the availability of sufficient financial resources.  </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Company is unable to obtain sufficient capital to continue to advance its programs, the Company would be forced to delay, reduce or eliminate its ongoing development and other activities.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">At-The-Market Equity Offering Program</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 12, 2015, </div>the Company filed a shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> (the “Registration Statement”), and entered into a Sales Agreement with Cowen and Company, LLC (the “Sales Agreement”) to establish an at-the-market (“ATM”) equity offering program pursuant to which they are able, with the Company’s authorization, to offer and sell up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40</div> million of the Company’s Common Stock at prevailing market prices from time to time. The Registration Statement became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 12, 2016. </div>The Company paid Cowen a commission equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3%</div> of the gross proceeds of the sales price of all shares sold through it as sales agent under the Sales Agreement. The offering costs were offset against proceeds from the sale of common stock under this agreement. The Company filed a prospectus supplement on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 16, 2017 </div>because the Company is currently subject to General Instruction <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">I.B.6</div> of Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> which limits the amounts that the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>sell under the Registration Statement. The Company’s ATM program was terminated effective as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 7, 2019, </div>when its new shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> File <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">228865,</div> was declared effective by the SEC. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">896,811</div> shares of Common Stock under the Sales Agreement for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million offset by total offering costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div> shares of Common Stock under the Sales Agreement for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>total offering costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$46,000,</div> were offset against the proceeds from the sale of common stock. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div> shares of Common Stock sold under the ATM program during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>were all sold on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 25, 2018 </div>to New Leaf Venture Partners LLC.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Series A Preferred Financing</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 22, 2017, </div>the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a syndicate of current and new institutional investors, led by an affiliate of Deerfield Management Company, L.P., pursuant to which the Company agreed to issue and sell to the “Investors” an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,000</div> shares of the Company’s Series A Convertible Preferred Stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share (the “Transaction”), for a purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> per share, or an aggregate gross purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.0</div> million, all upon the terms and conditions set forth in the Purchase Agreement. The Company closed this Transaction on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2, 2017 (</div>see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div>).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2, 2017, </div>the Company entered into a registration rights agreement with the Investors (the “Registration Rights Agreement”). On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 3, 2017, </div>in accordance with the Registration Rights Agreement, the Company filed a registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> to register the common stock issuable upon conversion of the Preferred Shares. The registration statement became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 21, 2017.</div></div></div>
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2985000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23049000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	208000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18427000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16099000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19916000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23233000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22352000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23687000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-20729000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-29964000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-28526000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20729000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36711000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28526000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	643000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	398000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	179000
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018	us-gaap	Operating Expenses OperatingExpenses	21372000
CY2017	us-gaap	Operating Expenses OperatingExpenses	30362000
CY2016	us-gaap	Operating Expenses OperatingExpenses	28705000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	6365000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	5000000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	4622000
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	5385000
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	6480000
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5986000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	12306000
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	5590000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-21372000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-30362000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-28705000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	207000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	207000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	218000
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-20000
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	207000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	139000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2016	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2018	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	15443000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	32942000
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	39756000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	271000
CY2017	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount
CY2018	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments
CY2017	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	6747000
CY2016	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1369000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1339000
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	31990000
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	16878000
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1999000
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	197000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1090000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	971000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	263000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	259000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11848000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21686000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18869000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	22000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	404000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2681072
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.12
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4597226
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.18
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.12
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	404000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4597226
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	22000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	3429000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3227000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	3343000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0255
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0209
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0145
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.935
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.945
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.844
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2067356
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.57
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	27000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	42013
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	83433
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2041600
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	719337
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	132495
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.61
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.08
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	121000
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	13.30
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.82
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.11
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.61
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y25D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	241000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y255D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y292D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y146D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y146D
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	11000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	130000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	132000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1288000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2853000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	63405000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	38441000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	34739000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	20443000
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	3100000
CY2017Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	2300000
CY2016Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-54100000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8800000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18102219
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17274326
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16561799
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17674729
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17674729
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17824186
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19221292
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16636201
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17207672
CY2017Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17619418

Files In Submission

Name	View Source	Status
0001171843-19-001687-index-headers.html	Edgar Link	pending
0001171843-19-001687-index.html	Edgar Link	pending
0001171843-19-001687.txt	Edgar Link	pending
0001171843-19-001687-xbrl.zip	Edgar Link	pending
exh_211.htm	Edgar Link	pending
exh_231.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
f10k_031219p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fistulause.jpg	Edgar Link	pending
graph_1.jpg	Edgar Link	pending
proportionpatent.jpg	Edgar Link	pending
prto-20181231.xml	Edgar Link	completed
prto-20181231.xsd	Edgar Link	pending
prto-20181231_cal.xml	Edgar Link	unprocessable
prto-20181231_def.xml	Edgar Link	unprocessable
prto-20181231_lab.xml	Edgar Link	unprocessable
prto-20181231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
secondarypatency.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TARA
Protara Therapeutics, Inc. Stock $tara

2019 Q1 Form 10-K Financial Statement

#000117184319001687 Filed on March 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TARA Protara Therapeutics, Inc. Stock $tara

2019 Q1 Form 10-K Financial Statement

#000117184319001687 Filed on March 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TARA
Protara Therapeutics, Inc. Stock $tara